EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Schlagwort(e): Prognose/Prognoseänderung SCHOTT Pharma präzisiert die Prognose für Umsatzwachstum und EBITDA-Marge für das Geschäftsjahr 2025
SCHOTT Pharma präzisiert die Prognose für das Geschäftsjahr 2025:
Weitere Informationen und vorläufige Zahlen für das dritte Quartal 2025 sowie die ersten neun Monate finden Sie in unserer ergänzenden Pressemitteilung. Die vollständigen Finanzergebnisse für das dritte Quartal und die ersten neun Monate 2025 werden am 12. August 2025 veröffentlicht. Kontakt Lea Kaiser PR & Communications Manager Tel.: +49 (0) 151 68917195 E-Mail: lea.kaiser@schott.com Tobias Erfurth Head of Investor Relations E-Mail: ir.pharma@schott.com Jasko Terzic, CFA Senior Manager Investor Relations E-Mail: ir.pharma@schott.com Ende der Insiderinformation
05.08.2025 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
Sprache: | Deutsch |
Unternehmen: | SCHOTT Pharma AG & Co. KGaA |
Hattenbergstraße 10 | |
55122 Mainz | |
Deutschland | |
ISIN: | DE000A3ENQ51 |
WKN: | A3ENQ5 |
Indizes: | SDAX |
Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart, Tradegate Exchange |
EQS News ID: | 2179338 |
Ende der Mitteilung | EQS News-Service |
|
2179338 05.08.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.